Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | CCR8 | P51685 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16088780 | 0.90 | TP53 (0.66) | ALBALDH1A1TP53NPC1RAB9A | |
| SCHEMBL17531739 | 0.90 | CCR8 (0.66) | ALBALDH1A1TP53NPC1RAB9A | |
| SCHEMBL16088783 | 0.88 | HTT (0.64) | ALBALDH1A1TP53NPC1RAB9A | |
| SCHEMBL16127708 | 0.85 | CNR1 (0.69) | ALBALDH1A1TP53MEN1KMT2A | |
| SCHEMBL16088726 | 0.85 | MEN1 (0.59) | ALBALDH1A1TP53MEN1KMT2A | |
| SCHEMBL23864543 | 0.84 | MEN1 (0.58) | ALBALDH1A1TP53SMN1; SMN2MEN1 | |
| SCHEMBL16088767 | 0.84 | CCR8 (0.65) | ALBALDH1A1TP53SMN1; SMN2MEN1 | |
| SCHEMBL16127703 | 0.83 | ALDH1A1 (0.70) | ALBALDH1A1TP53NPC1RAB9A | |
| SCHEMBL16088777 | 0.81 | POLB (0.63) | ALDH1A1TP53MEN1KMT2ACCR8 | |
| SCHEMBL16127833 | 0.81 | POLB (0.63) | ALDH1A1TP53MEN1KMT2ACCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452170-B2 | Compounds and methods for inducing chondrogenesis | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160045514-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045514-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | COL2A1, BMP4, COL1A1 | ALB 4009/4885ALDH1A1 52/4885TP53 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.